300406 九强生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)6.60614.97312.66313.3624.340
总资产报酬率 ROA (%)4.78110.7018.7129.7943.671
投入资产回报率 ROIC (%)5.04011.2699.23010.7323.129

边际利润分析
销售毛利率 (%)77.32874.66474.59072.06561.492
营业利润率 (%)36.83134.09930.14733.50518.045
息税前利润/营业总收入 (%)39.05436.50432.93234.71116.541
净利润/营业总收入 (%)30.37429.97626.10829.36514.347

收益指标分析
经营活动净收益/利润总额(%)100.89699.276104.893102.446135.002
价值变动净收益/利润总额(%)0.4653.4984.2452.1480.881
营业外收支净额/利润总额(%)-0.689-0.054-1.3650.208-11.772

偿债能力分析
流动比率 (X)10.3617.8566.9362.8657.305
速动比率 (X)9.4647.0836.1992.4516.285
资产负债率 (%)27.34528.09629.13832.55713.629
带息债务/全部投入资本 (%)22.64423.25125.03427.848--
股东权益/带息债务 (%)337.685327.415296.779256.2031,072.743
股东权益/负债合计 (%)266.101256.127243.373204.385591.917
利息保障倍数 (X)15.77515.06410.32130.56241.779

营运能力分析
应收账款周转天数 (天)244.147218.230229.676187.2160.000
存货周转天数 (天)219.915183.318221.139201.2190.000